BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.

Current Report (Form 8-K | Period ending 2025-12-16)

Current Report (Form 8-K | Period ending 2025-12-17)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

BeOne (ONC US)

Current Report (Form 8-K | Period ending 2025-12-16)

Current Report (Form 8-K | Period ending 2025-12-17)

Current Report (Form 8-K | Period ending 2025-11-13)

Quarterly Report (Form 10-Q | Period ending 2025-09-30)

Current Report (Form 8-K | Period ending 2025-11-06)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)